Frequently Asked Questions
Short, plain-English answers, each with a link to the page that goes deeper.
Last updated
Costs
What does GLP-1 telehealth cost?
It depends on the program, the medication, your dose, and whether insurance pays for any of it. Many programs charge a membership or visit fee, and the medication may be billed separately. See how costs break down.
What can a headline price leave out?
Labs, follow-up visits, shipping, and higher-dose pricing may be separate. Before you pay, ask for the full monthly cost after the first few months. Read our cost guide.
Does insurance cover GLP-1 medications?
Some plans do and some don’t, and it can depend on why the medication is prescribed. Your insurer can tell you whether it’s covered and whether you need prior authorization. Compare insurance and cash-pay.
Do you need insurance to use a telehealth program?
Not usually. Many programs accept cash payment, which means you pay the program and medication costs yourself for as long as you stay on treatment. Plan for the long-term cost.
Access
How does GLP-1 telehealth work?
You complete an online intake, and a licensed clinician reviews it by message or video. They may order labs. If they decide a medication is appropriate, they prescribe it and a pharmacy ships it to you. See each step.
Who is eligible for a GLP-1?
Only a licensed clinician can decide that. NIH says medication may be prescribed for adults with a BMI of 30 or greater, or 27 or greater with weight-related health problems. Your health history matters too. Read about screening.
Is online GLP-1 telehealth legit?
It can be. Look for licensed clinicians, a real prescription requirement, a named pharmacy, and clear cancellation terms. The FDA lists not requiring a prescription as a warning sign. Use our legit program checklist.
Are compounded GLP-1 products FDA-approved?
No. Compounded medications are not FDA-approved, and they are not the same as FDA-approved products. The FDA does not verify their safety, effectiveness, or quality before they are marketed. Learn about brand-name and compounded options.
Safety
What are the most common side effects?
Digestive side effects are the most common, including nausea, diarrhea, vomiting, and constipation. They are more likely in the first weeks and with dose increases. Your experience may differ. See what the labels report.
What serious risks should I know about?
The semaglutide, tirzepatide, and orforglipron labels include a boxed warning about thyroid C-cell tumors, along with warnings on pancreatitis, gallbladder problems, low blood sugar with certain medications, and kidney problems from dehydration. Ask your clinician how these apply to you. Read the risks and warning signs.
What does the orforglipron label say about safety?
The orforglipron (Foundayo) label lists nausea, constipation, diarrhea, and vomiting among the most common side effects. In its trials, 26–35% of people reported nausea, depending on dose, compared with 10% on placebo. It carries a boxed warning about thyroid C-cell tumors, and it also warns about pancreatitis, gallbladder problems, and kidney problems from dehydration. Ask a licensed provider how these apply to you. Read the orforglipron safety section.
When should I get emergency care?
Call 911 or go to the nearest emergency room for severe symptoms, such as trouble breathing, swelling of your face or throat, chest pain, or severe stomach pain. Don’t wait, and don’t rely on a website. Read our medical disclaimer.
Under 35
Can you get a GLP-1 in your 20s?
Adults in their 20s are evaluated the same way as other adults. A licensed clinician decides based on your health and history, so age alone doesn’t settle it either way. Read our under 35 guide.
What happens if I stop taking a GLP-1?
NIH says you will probably regain some weight after stopping weight management medication, and trials found substantial regain on average. Talk to your clinician before you stop or change a medication. See what the trials found.
Do GLP-1s affect birth control or pregnancy plans?
They can. The tirzepatide label says it may reduce how well oral contraceptive pills work, and the semaglutide label says to stop at least 2 months before a planned pregnancy. The orforglipron (Foundayo) label says it may make birth control pills work less well, and it advises a non-oral method or an added barrier method for 30 days after starting and after each dose increase. Raise this at your first visit. Read about planning ahead.
Should I strength train while taking a GLP-1?
A joint advisory from four professional groups says strength training and enough protein help preserve muscle and bone. The CDC recommends muscle-strengthening activity 2 days a week for all adults. Ask a clinician what fits you. Read about muscle and nutrition.
This Site
Who runs GLP-1 Unpacked?
GLP-1 Unpacked is an independent educational resource run by Terry Rossi, a sole proprietor in Florida. We are not doctors, a pharmacy, or a telehealth company. About us.
How does this site make money?
This site may include affiliate links, so we may earn a commission if you sign up through one, at no extra cost to you. We don’t have any yet, and we’ll mark them clearly once we do. Affiliate relationships never change our rankings. Read our affiliate disclosure.
Is this medical advice?
No. Everything here is general education, and reading it doesn’t create a doctor-patient relationship. Talk to a licensed provider about your own health. Read the full disclaimer.
How do I report a mistake?
Email us, and we’ll review it. We review every correction we receive, and we date our pages so you can see how fresh they are. Contact us.
Sources
We read each of these pages on November 1, 2026. Rules and labeling change, so check the source for the current version.
- Prescription Medications to Treat Overweight & Obesity. National Institute of Diabetes and Digestive and Kidney Diseases (NIH), last reviewed June 2024.
- Compounding and the FDA: Questions and Answers. U.S. Food and Drug Administration, current as of September 16, 2025.
- How to Buy Medicines Safely From an Online Pharmacy. U.S. Food and Drug Administration, current as of January 2, 2025.
- Semaglutide injection and tablets prescribing information. DailyMed, U.S. National Library of Medicine, revised June 2026.
- Tirzepatide injection prescribing information. DailyMed, U.S. National Library of Medicine, revised August 2026.
- Orforglipron tablets prescribing information (PDF). Eli Lilly and Company, revised July 2026.
- Nutritional priorities to support GLP-1 therapy for obesity: a joint Advisory. American College of Lifestyle Medicine, American Society for Nutrition, Obesity Medicine Association, and The Obesity Society. Obesity Pillars, 2026.
- Adult Activity: An Overview. U.S. Centers for Disease Control and Prevention, December 20, 2023.